Schenberg EE
Instituto Phaneros, São Paulo, Brazil.
ArticlePsychedelics
Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design.
ArticlePsilocybin
From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice.
PreprintMDMA
Evidence-Based Medicine is inadequate to develop evidence-based psychedelic therapies.
PreprintPsilocybin
From efficacy to effectiveness: evaluating psychedelic randomised controlled trials for trustworthy evidence-based policy and practice.
PreprintPsilocybin
From efficacy to effectiveness: evaluating psychedelic randomised controlled trials for trustworthy evidence-based policy and practice.
ArticlePsilocybin
Is Poorly Assisted Psilocybin Treatment an Increasing Risk?
ArticleAyahuasca
Emotion regulation effects of Ayahuasca in experienced subjects during implicit aversive stimulation: An fMRI study.
ArticlePsychedelics
Psychedelic drugs as new tools in psychiatric therapeutics.
ArticleMDMA
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil.
ArticlePsilocybin
Ethical Concerns about Psilocybin Intellectual Property.
ArticlePsilocybin
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.
ArticleLSD
Neural correlates of the LSD experience revealed by multimodal neuroimaging.
ArticleAyahuasca
Acute Biphasic Effects of Ayahuasca.
ArticleAyahuasca